<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37315513</PMID><DateCompleted><Year>2023</Year><Month>06</Month><Day>16</Day></DateCompleted><DateRevised><Year>2023</Year><Month>06</Month><Day>17</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2161-5853</ISSN><JournalIssue CitedMedium="Internet"><Volume>31</Volume><Issue>3</Issue><PubDate><Year>2023</Year><Month>May</Month></PubDate></JournalIssue><Title>Topics in antiviral medicine</Title><ISOAbbreviation>Top Antivir Med</ISOAbbreviation></Journal><ArticleTitle>CROI 2023: Acute and Post-Acute COVID-19.</ArticleTitle><Pagination><StartPage>493</StartPage><EndPage>509</EndPage><MedlinePgn>493-509</MedlinePgn></Pagination><Abstract><AbstractText>Studies of acute and post-acute COVID-19 were presented at the 2023 Conference on Retroviruses and Opportunistic Infections (CROI). Early treatment with ensitrelvir, a novel protease inhibitor, hastened viral clearance and symptom resolution during coronavirus disease 2019 (COVID-19) and appeared to reduce the prevalence of long COVID symptoms. The development of novel agents against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), including those with broader sarbecovirus activity such as anti-angiotensin-converting enzyme 2 monoclonal antibodies, is underway. A growing understanding of the pathophysiology of long COVID has provided several potential therapeutic targets for individuals experiencing this condition. Efforts to understand COVID-19 in people with HIV have led to novel insights into the biology and natural history of SARS-CoV-2 coinfection in this vulnerable subpopulation. These and other studies are summarized herein.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Antar</LastName><ForeName>Annukka A R</ForeName><Initials>AAR</Initials><AffiliationInfo><Affiliation>Johns Hopkins University, Baltimore, Maryland, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Peluso</LastName><ForeName>Michael J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>University of California San Francisco, California, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Top Antivir Med</MedlineTA><NlmUniqueID>101560274</NlmUniqueID><ISSNLinking>2161-5853</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>PX665RAA3H</RegistryNumber><NameOfSubstance UI="C000722354">ensitrelvir</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012192" MajorTopicYN="Y">Retroviridae Infections</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>6</Month><Day>16</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>6</Month><Day>15</Day><Hour>1</Hour><Minute>8</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>6</Month><Day>14</Day><Hour>18</Hour><Minute>11</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>5</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37315513</ArticleId><ArticleId IdType="pmc">PMC10266867</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Gao YD, Ding M, Dong X, et al. Risk factors for severe and critically ill COVID-19 patients: a review. Allergy. 2021;76(2):428&#x2013;455. doi:10.1111/all.14657</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/all.14657</ArticleId><ArticleId IdType="pubmed">33185910</ArticleId></ArticleIdList></Reference><Reference><Citation>Tenforde MW, Self WH, Gaglani M, et al. Effectiveness of mRNA vaccination in preventing COVID-19-associated invasive mechanical ventilation and death-United States, March 2021-January 2022. MMWR Morb Mortal Wkly Rep. 2022;71(12):459&#x2013;465. doi:10.15585/mmwr.mm7112e1</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm7112e1</ArticleId><ArticleId IdType="pmc">PMC8956334</ArticleId><ArticleId IdType="pubmed">35324878</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewnard JA, McLaughlin JM, Malden D, et al. Effectiveness of nirmatrelvir-ritonavir in preventing hospital admissions and deaths in people with COVID-19: a cohort study in a large US health-care system. Lancet Infect Dis. 2023 March 15. (Online ahead of print). doi:10.1016/S1473-3099(23)00118-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(23)00118-4</ArticleId><ArticleId IdType="pmc">PMC10081864</ArticleId><ArticleId IdType="pubmed">36933565</ArticleId></ArticleIdList></Reference><Reference><Citation>Wongvibulsin S, Garibaldi BT, Antar AAR, et al. Development of evere COVID-19 adaptive risk predictor (SCARP), a calculator to predict severe disease or death in hospitalized patients with COVID-19. Ann Intern Med. 2021;174(6):777&#x2013;785. doi:10.7326/M20-6754</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/M20-6754</ArticleId><ArticleId IdType="pmc">PMC7934337</ArticleId><ArticleId IdType="pubmed">33646849</ArticleId></ArticleIdList></Reference><Reference><Citation>Buttia C, Llanaj E, Raeisi-Dehkordi H, et al. Prognostic models in COVID-19 infection that predict severity: a systematic review. Eur J Epidemiol. 2023;1&#x2013;18. doi:10.1007/s10654-023-00973-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10654-023-00973-x</ArticleId><ArticleId IdType="pmc">PMC9958330</ArticleId><ArticleId IdType="pubmed">36840867</ArticleId></ArticleIdList></Reference><Reference><Citation>Bastard P, Rosen LB, Zhang Q, et al. Autoantibodies against type I IFNs in patients with life-threatening COVID-19. Science. 2020;370(6515). doi:10.1126/science.abd4585</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abd4585</ArticleId><ArticleId IdType="pmc">PMC7857397</ArticleId><ArticleId IdType="pubmed">32972996</ArticleId></ArticleIdList></Reference><Reference><Citation>Hammond J, Leister-Tebbe H, Gardner A, et al. Oral mirmatrelvir for high-risk, nonhospitalized adults with COVID-19. N Engl J Med. 2022;386(15):1397&#x2013;1408. doi:10.1056/NEJMoa2118542</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2118542</ArticleId><ArticleId IdType="pmc">PMC8908851</ArticleId><ArticleId IdType="pubmed">35172054</ArticleId></ArticleIdList></Reference><Reference><Citation>
COVID-19 Treatment Guidelines. Antiviral agents, including antibody products summary recommendations. Accessed May 10, 2023. https://www.covid19treatmentguidelines.nih.gov/therapies/antivirals-including-antibody-products/summary-recommendations/</Citation></Reference><Reference><Citation>Bramante CT, Huling JD, Tignanelli CJ, et al. Randomized trial of metformin, ivermectin, and fluvoxamine for COVID-19. N Engl J Med. 2022;387(7):599&#x2013;610. doi:10.1056/NEJMoa2201662</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2201662</ArticleId><ArticleId IdType="pmc">PMC9945922</ArticleId><ArticleId IdType="pubmed">36070710</ArticleId></ArticleIdList></Reference><Reference><Citation>Xian H, Liu Y, Rundberg NA, et al. Metformin inhibition of mitochondrial ATP and DNA synthesis abrogates NLRP3 inflammasome activation and pulmonary inflammation. Immunity. 2021;54(7):1463&#x2013;1477. doi:10.1016/j.immuni.2021.05.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2021.05.004</ArticleId><ArticleId IdType="pmc">PMC8189765</ArticleId><ArticleId IdType="pubmed">34115964</ArticleId></ArticleIdList></Reference><Reference><Citation>Watson OJ, Barnsley G, Toor J, Hogan AB, Winskill P, Ghani AC. Global impact of the first year of COVID-19 vaccination: a mathematical modelling study. Lancet Infect Dis. 2022;22(9):1293&#x2013;1302. doi:10.1016/S1473-3099(22)00320-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(22)00320-6</ArticleId><ArticleId IdType="pmc">PMC9225255</ArticleId><ArticleId IdType="pubmed">35753318</ArticleId></ArticleIdList></Reference><Reference><Citation>Bobrovitz N, Ware H, Ma X, et al. Protective effectiveness of previous SARS-CoV-2 infection and hybrid immunity against the omicron variant and severe disease: a systematic review and meta-regression. Lancet Infect Dis. 2023;23(5):556&#x2013;567. doi:10.1016/S1473-3099(22)00801-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(22)00801-5</ArticleId><ArticleId IdType="pmc">PMC10014083</ArticleId><ArticleId IdType="pubmed">36681084</ArticleId></ArticleIdList></Reference><Reference><Citation>
Mathieu E, Ritchie H, Ortiz-Ospina E, et al. Corona-virus (COVID-19) vaccinations. Our World in Data. Accessed May 10, 2023. https://ourworldindata.org/covid-vaccinations?country=OWID_WRL</Citation></Reference><Reference><Citation>Kunyenje CA, Chirwa GC, Mboma SM, et al. COVID-19 vaccine inequity in African low-income countries. Front Public Health. 2023;11):1087662. doi:10.3389/fpubh.2023.1087662</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fpubh.2023.1087662</ArticleId><ArticleId IdType="pmc">PMC10025287</ArticleId><ArticleId IdType="pubmed">36950103</ArticleId></ArticleIdList></Reference><Reference><Citation>Douaud G, Lee S, Alfaro-Almagro F, et al. SARS-CoV-2 is associated with changes in brain structure in UK Biobank 1. Nature. 2022;604(7907):697&#x2013;707. doi:10.1038/s41586-022-04569-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-04569-5</ArticleId><ArticleId IdType="pmc">PMC9046077</ArticleId><ArticleId IdType="pubmed">35255491</ArticleId></ArticleIdList></Reference><Reference><Citation>Su Y, Yuan D, Chen DG, et al. Multiple early factors anticipate post-acute COVID-19 sequelae. Cell. 2022;185(5):881&#x2013;895. doi:10.1016/j.cell.2022.01.014</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2022.01.014</ArticleId><ArticleId IdType="pmc">PMC8786632</ArticleId><ArticleId IdType="pubmed">35216672</ArticleId></ArticleIdList></Reference><Reference><Citation>Nalbandian A, Sehgal K, Gupta A, et al. Post-acute COVID-19 syndrome. Nat Med. 2021;27(4):601&#x2013;615. doi:10.1038/s41591-021-01283-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01283-z</ArticleId><ArticleId IdType="pmc">PMC8893149</ArticleId><ArticleId IdType="pubmed">33753937</ArticleId></ArticleIdList></Reference><Reference><Citation>Peluso MJ, Deeks SG. Early clues regarding the pathogenesis of long-COVID. Trends Immunol. 2022;43(4):268&#x2013;270. doi:10.1016/j.it.2022.02.008</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.it.2022.02.008</ArticleId><ArticleId IdType="pmc">PMC8901423</ArticleId><ArticleId IdType="pubmed">35272932</ArticleId></ArticleIdList></Reference><Reference><Citation>Wulf-Hanson S, Abbafati C, Aerts JG, et al. Estimated global proportions of individuals with persistent fatigue, cognitive, and respiratory symptom clusters following symptomatic COVID-19 in 2020 and 2021. JAMA. 2022;328(16):1604&#x2013;1615. doi:10.1001/jama.2022.18931</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2022.18931</ArticleId><ArticleId IdType="pmc">PMC9552043</ArticleId><ArticleId IdType="pubmed">36215063</ArticleId></ArticleIdList></Reference><Reference><Citation>Perlis RH, Santillana M, Ognyanova K, et al. Prevalence and correlates of long COVID symptoms among US adults. JAMA Netw Open. 2022;5(10):e2238804. doi:10.1001/jamanetworkopen.2022.38804</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2022.38804</ArticleId><ArticleId IdType="pmc">PMC9614581</ArticleId><ArticleId IdType="pubmed">36301542</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang H, Zang C, Xu Z, et al. Data-driven identification of post-acute SARS-CoV-2 infection subphenotypes. Nat Med. 2023;29(1):226&#x2013;235. doi:10.1038/s41591-022-02116-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-02116-3</ArticleId><ArticleId IdType="pmc">PMC9873564</ArticleId><ArticleId IdType="pubmed">36456834</ArticleId></ArticleIdList></Reference><Reference><Citation>Peluso MJ, Kelly JD, Lu S, et al. Persistence, magnitude, and patterns of postacute symptoms and quality of life following onset of SARS-CoV-2 infection: cohort description and approaches for measurement. Open Forum Infect Dis. 2022;9(2):ofab640. doi:10.1093/ofid/ofab640</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ofid/ofab640</ArticleId><ArticleId IdType="pmc">PMC8755302</ArticleId><ArticleId IdType="pubmed">35106317</ArticleId></ArticleIdList></Reference><Reference><Citation>Kenny G, McCann K, O'Brien C, et al. Identification of distinct long COVID clinical phenotypes through cluster analysis of self-reported symptoms. Open Forum Infect Dis. 2022;9(4):ofac060. doi:10.1093/ofid/ofac060</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ofid/ofac060</ArticleId><ArticleId IdType="pmc">PMC8900926</ArticleId><ArticleId IdType="pubmed">35265728</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis HE, McCorkell L, Vogel JM, Topol EJ. Long COVID: major findings, mechanisms and recommendations. Nat Rev Microbiol. 2023;21(3):133&#x2013;146. doi:10.1038/s41579-022-00846-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-022-00846-2</ArticleId><ArticleId IdType="pmc">PMC9839201</ArticleId><ArticleId IdType="pubmed">36639608</ArticleId></ArticleIdList></Reference><Reference><Citation>Swank Z, Senussi Y, Manickas-Hill Z, et al. Persistent circulating severe acute respiratory syndrome coronavirus 2 spike is associated with post-acute coronavirus disease 2019 sequelae. Clin Infect Dis. 2023;76(3):e487&#x2013;e490. doi:10.1093/cid/ciac722</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciac722</ArticleId><ArticleId IdType="pmc">PMC10169416</ArticleId><ArticleId IdType="pubmed">36052466</ArticleId></ArticleIdList></Reference><Reference><Citation>Giron LB, Peluso MJ, Ding J, et al. Markers of fungal translocation are elevated during post-acute sequelae of SARS-CoV-2 and induce NF-kappaB signaling. JCI Insight. 2022;7(15):160989. doi:10.1172/jci.insight.160989</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci.insight.160989</ArticleId><ArticleId IdType="pmc">PMC9462470</ArticleId><ArticleId IdType="pubmed">35727635</ArticleId></ArticleIdList></Reference><Reference><Citation>Peluso MJ, Sans HM, Forman CA, et al. Plasma markers of neurologic injury and inflammation in people with self-reported neurologic postacute sequelae of SARS-CoV-2 infection. Neurol Neuroimmunol Neuroinflamm. 2022;9(5):e200003. doi:10.1212/NXI.0000000000200003</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/NXI.0000000000200003</ArticleId><ArticleId IdType="pmc">PMC9210548</ArticleId><ArticleId IdType="pubmed">35701186</ArticleId></ArticleIdList></Reference><Reference><Citation>Gold JE, Okyay RA, Licht WE, Hurley DJ. Investigation of long COVID prevalence and its relationship to Epstein-Barrvirusreactivation. Pathogens. 2021;10(6):10060763. doi:10.3390/pathogens10060763</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/pathogens10060763</ArticleId><ArticleId IdType="pmc">PMC8233978</ArticleId><ArticleId IdType="pubmed">34204243</ArticleId></ArticleIdList></Reference><Reference><Citation>Peluso MJ, Deveau TM, Munter SE, et al. Chronic viral coinfections differentially affect the likelihood of developing long COVID. J Clin Invest. 2023;133(3):163669. doi:10.1172/JCI163669</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI163669</ArticleId><ArticleId IdType="pmc">PMC9888380</ArticleId><ArticleId IdType="pubmed">36454631</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang SE, Feng A, Meng W, et al. New-onset IgG autoantibodies in hospitalized patients with COVID-19. Nat Commun. 2021;12(1):5417. doi:10.1038/s41467-21-25509-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-21-25509-3</ArticleId><ArticleId IdType="pmc">PMC8440763</ArticleId><ArticleId IdType="pubmed">34521836</ArticleId></ArticleIdList></Reference><Reference><Citation>Roessler M, Tesch F, Batram M, et al. Post-COVID-19-associated morbidity in children, adolescents, and adults: a matched cohort study including more than 157,000 individuals with COVID-19 in Germany. PLoS Med. 2022;19(11):e1004122. doi:10.1371/journal.pmed.1004122</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pmed.1004122</ArticleId><ArticleId IdType="pmc">PMC9648706</ArticleId><ArticleId IdType="pubmed">36355754</ArticleId></ArticleIdList></Reference><Reference><Citation>Pretorius E, Venter C, Laubscher GJ, et al. Prevalence of symptoms, comorbidities, fibrin amyloid microclots and platelet pathology in individuals with long COVID/post-acute sequelae of COVID-19 (PASC). Cardiovasc Diabetol. 2022;21(1):148. doi:10.1186/s12933-22-01579-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12933-22-01579-5</ArticleId><ArticleId IdType="pmc">PMC9356426</ArticleId><ArticleId IdType="pubmed">35933347</ArticleId></ArticleIdList></Reference><Reference><Citation>Peluso MJ, Deeks SG, Mustapic M, et al. SARS-CoV-2 and mitochondrial proteins in neural-derived exosomes of COVID-19. Ann Neurol. 2022;91(6):772&#x2013;781. doi:10.1002/ana.26350</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.26350</ArticleId><ArticleId IdType="pmc">PMC9082480</ArticleId><ArticleId IdType="pubmed">35285072</ArticleId></ArticleIdList></Reference><Reference><Citation>Peluso MJ, Spinelli MA, Deveau TM, et al. Post-acute sequelae and adaptive immune responses in people with HIV recovering from SARS-COV-2 infection. AIDS. 2022;36(12):F7&#x2013;F16. doi:10.1097/QAD.0000000000003338</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/QAD.0000000000003338</ArticleId><ArticleId IdType="pmc">PMC9444925</ArticleId><ArticleId IdType="pubmed">35866847</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>